Status:

WITHDRAWN

Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis

Lead Sponsor:

Temple University

Conditions:

Venous Thrombosis

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

PHASE2

Brief Summary

99mTc-rBitistatin is a radiolabeled polypeptide which is designed to stick to blood clots so that the blood clots can be detected by imaging. The purpose of this trial is to evaluate in patients the s...

Eligibility Criteria

Inclusion

  • peripheral acute venous thrombosis diagnosed by vascular ultrasound
  • is able to give informed consent
  • is likely to complete the study

Exclusion

  • is pregnant
  • is lactating
  • has a history of prior severe allergic reactions (anaphylactic response)
  • prior use of GP IIb/IIIa antagonist (e.g., abciximab, eptifibatide)
  • has a platelet count \<100,000 or history of thrombocytopenia
  • has a history of stroke
  • has a history of recent bleeding documented by decreasing hemoglobin (\>1 gm) in last 7 days

Key Trial Info

Start Date :

December 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2017

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00808626

Start Date

December 1 2008

End Date

March 1 2017

Last Update

May 4 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Temple University Hospital

Philadelphia, Pennsylvania, United States, 19140

Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis | DecenTrialz